ivosidenib (AG-120)

DRUG2 trials

Sponsors

Agios Pharmaceuticals, Inc.

Conditions

Acute Myeloid LeukemiaHealthyRelapsed Adult AMLRelapsed Pediatric AML

Phase 1

Japanese Bridging Study of Ivosidenib (AG-120) in Healthy Subjects

CompletedNCT03071770

Agios Pharmaceuticals, Inc.Healthy

Start: 2017-03-31End: 2017-09-06Updated: 2018-01-11

Unknown Phase

Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 Mutation

Agios Pharmaceuticals, Inc.Acute Myeloid Leukemia, Relapsed Adult AML, Relapsed Pediatric AML

Updated: 2018-07-24

Related Papers

Effect of itraconazole, food, and ethnic origin on the pharmacokinetics of ivosidenib in healthy subjects

European Journal of Clinical Pharmacology2019-04-2230 citations